WithdrawnPhase 2NCT02588625

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Bristol-Myers Squibb
Principal Investigator: Bristol Myers Squibb
Bristol-Myers Squibb
Intervention: BMS-986020(drug)
Eligibility: 18 years · All sexes
Timeline: 2016 – 2019

Study locations (24)

Local Institution, Scottsdale, Arizona, United States
Local Institution, Los Angeles, California, United States
Local Institution, Stanford, California, United States
Local Institution, Aurora, Colorado, United States
Local Institution, Washington D.C., District of Columbia, United States
Local Institution, Chicago, Illinois, United States
Local Institution, Baltimore, Maryland, United States
Local Institution, Boston, Massachusetts, United States
Local Institution, Ann Arbor, Michigan, United States
Local Institution, New Brunswick, New Jersey, United States
Local Institution, Albany, New York, United States
Local Institution, New York, New York, United States
Local Institution, Cleveland, Ohio, United States
Local Institution, Pittsburgh, Pennsylvania, United States
Local Institution, Charleston, South Carolina, United States
+9 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02588625 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials